Biological role of aldo-keto reductases in retinoic acid biosynthesis and signaling

Frontiers in Pharmacology

Volumn 3 APR, Issue , 2012, Pages

  Ruiz, F Xavier ^a,b   Porté, Sergio ^a   Parés, Xavier ^a   Farrés, Jaume ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

Aldo keto reductase; Cancer; Retinaldehyde; Retinoic acid; Retinol

Indexed keywords

ALCOHOL DEHYDROGENASE; ALDEHYDE DEHYDROGENASE; ALDO KETO REDUCTASE; ALDO KETO REDUCTASE 1B1; ALDO KETO REDUCTASE 1B10; ALDO KETO REDUCTASE 1B12; ALDO KETO REDUCTASE C1; ALDO KETO REDUCTASE C3; ALDO KETO REDUCTASE INHIBITOR; ALITRETINOIN; BETA CAROTENE; CAROTENOID; CELLULAR RETINOL BINDING PROTEIN 1; ENZYME INHIBITOR; FLUFENAMIC ACID; HORMONE RECEPTOR; LITHOCHOLIC ACID; OXIDOREDUCTASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PONALRESTAT; RETINAL; RETINALDEHYDE REDUCTASE; RETINOIC ACID; RETINOID X RECEPTOR; RETINOL; TOLRESTAT; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER GROWTH; CANCER RESISTANCE; CANCER RISK; CARCINOGENESIS; CELL COMPARTMENTALIZATION; CELL PROLIFERATION; DRUG DESIGN; DRUG TARGETING; ENDOPLASMIC RETICULUM; ENZYME ACTIVITY; ENZYME ASSAY; HORMONAL REGULATION; HUMAN; INTRACELLULAR SIGNALING; LEUKEMIA; LUNG CANCER; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR DYNAMICS; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; PROTEIN FUNCTION; RISK FACTOR; STRUCTURE ACTIVITY RELATION; VITAMIN METABOLISM; VITAMIN SUPPLEMENTATION;

EID: 84865715473     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2012.00058     Document Type: Article

References (79)

1. Barski, O. A., Gabbay, K. H., and Bohren, K. M. (1996). The Cterminal loop of aldehyde reductase determines the substrate and inhibitor specificity. Biochemistry 35, 14276-14280.
2. Barski, O. A., Tipparaju, S. M., and Bhatnagar, A. (2008). The aldo-keto reductase superfamily and its role in drug metabolism and detoxification. Drug Metab. Rev. 40, 553-624.
3. Belyaeva, O. V., Johnson, M. P., and Kedishvili, N. Y. (2008). Kinetic analysis of human enzyme RDH10 defines the characteristics of a physiologically relevant retinol dehydrogenase. J. Biol. Chem. 283, 20299-20308.
4. Belyaeva, O. V., and Kedishvili, N. Y. (2002). Human pancreas protein 2 (PAN2) has a retinal reductase activity and is ubiquitously expressed in human tissues. FEBS Lett. 531, 489-493.
5. Belyaeva, O. V., Korkina, O. V., Stetsenko, A. V., Kim, T., Nelson, P. S., and Kedishvili, N. Y. (2005). Biochemical properties of purified human retinol dehydrogenase 12 (RDH12): catalytic efficiency toward retinoids and C9 aldehydes and effects of cellular retinol-binding protein type I (CRBPI) and cellular retinaldehyde-binding protein (CRALBP) on the oxidation and reduction of retinoids. Biochemistry 44, 7035-7047.
6. Belyaeva, O. V., Stetsenko, A. V., Nelson, P., and Kedishvili, N. Y. (2003). Properties of short-chain dehydrogenase/reductase RalR1: characterization of purified enzyme, its orientation in the microsomal membrane, and distribution in human tissues and cell lines. Biochemistry 42, 14838-14845.
7. Blomhoff, R., and Blomhoff, H. K. (2006). Overview of retinoid metabolism and function. J. Neurobiol. 66, 606-630.
8. Cao, D., Fan, S. T., and Chung, S. S. (1998). Identification and characterization of a novel human aldose reductase-like gene. J. Biol. Chem. 273, 11429-11435.
9. Crosas, B., Cederlund, E., Torres, D., Jörnvall, H., Farrés, J., and Parés, X. (2001). A vertebrate aldoketo reductase active with retinoids and ethanol. J. Biol. Chem. 276, 19132-19140.
10. Crosas, B., Hyndman, D. J., Gallego, O., Martras, S., Parés, X., Flynn, T. G., and Farrés, J. (2003). Human aldose reductase and human small intestine aldose reductase are efficient retinal reductases: consequences for retinoid metabolism. Biochem. J. 373, 973-979.
11. Deng, H. B., Adikari, M., Parekh, H. K., and Simpkins, H. (2004). Ubiquitous induction of resistance to platinum drugs in human ovarian, cervical, germ-cell and lung carcinoma tumor cells overexpressing isoforms 1 and 2 of dihydrodiol dehydrogenase. Cancer Chemother. Pharmacol. 54, 301-307.
12. Desmond, J. C., Mountford, J. C., Drayson, M. T., Walker, E. A., Hewison,M.,Ride,J. P.,Luong,Q. T.,Hayden, R. E., Vanin, E. F., and Bunce, C. M. (2003). The aldo-keto reductase AKR1C3 is a novel suppressor of cell differentiation that provides a plausible target for the noncyclooxygenase-dependent antineoplastic actions of nonsteroidal antiinflammatory drugs. Cancer Res. 63, 505-512.
13. Díez-Dacal, B., Gayarre, J., Gharbi, S., Timms, J. F., Coderch, C., Gago, F., and Pérez-Sala, D. (2011). Identification of aldo-keto reductase AKR1B10 as a selective target for modification and inhibition by prostaglandin A(1): implications for antitumoral activity. Cancer Res. 71, 4161-4171.
14. Ebert, B., Kisiela, M., Wsol, V., and Maser, E. (2011). Proteasome inhibitors MG-132 and bortezomib induce AKR1C1, AKR1C3, AKR1B1, and AKR1B10 in human colon cancer cell lines SW-480 and HT-29. Chem. Biol. Interact. 191, 239-249.
15. El-Kabbani, O., and Podjarny, A. (2007). Selectivity determinants of the aldose and aldehyde reductase inhibitor-binding sites. Cell. Mol. Life Sci. 64, 1970-1978.
16. Endo, K., Fukui, M., Mishima, M., and Watanabe, K. (2001). Metabolism of vitamin A affected by prostaglandin F synthase in contractile interstitial cells of bovine lung. Biochem. Biophys. Res. Commun. 287, 956-961.
17. Endo, S., Matsunaga, T., Fujita, A., Tajima,K.,El-Kabbani,O.,and Hara, A. (2010a). Rat aldose reductaselike protein (AKR1B14) efficiently reduces the lipid peroxidation product 4-oxo-2-nonenal. Biol. Pharm. Bull. 33, 1886-1890.
18. Endo, S., Matsunaga, T., Kuragano, T., Ohno, S., Kitade, Y., Tajima, K., ElKabbani, O., and Hara, A. (2010b). Properties and tissue distribution of a novel aldo-keto reductase encoding in a rat gene (Akr1b10). Arch. Biochem. Biophys. 503, 230-237.
19. Endo, S., Matsunaga, T., Horie, K., Tajima, K., Bunai, Y., Carbone, V., El-Kabbani, O., and Hara, A. (2007). Enzymatic characteristics of an aldo-keto reductase family protein (AKR1C15) and its localization in rat tissues. Arch. Biochem. Biophys. 465, 136-147.
20. Endo, S., Matsunaga, T., Mamiya, H., Hara, A., Kitade, Y., Tajima, K., and El-Kabbani, O. (2009). Characterization of a rat NADPH-dependent aldo-keto reductase (AKR1B13) induced by oxidative stress. Chem. Biol. Interact. 178, 151-157.
21. Farjo, K. M., Moiseyev, G., Nikolaeva, O., Sandell, L. L., Trainor, P. A., and Ma, J. X. (2011). RDH10 is the primary enzyme responsible for the first step of embryonic Vitamin A metabolism and retinoic acid synthesis. Dev. Biol. 357, 347-355.
22. Fukumoto, S.,Yamauchi, N., Moriguchi, H., Hippo, Y., Watanabe, A., Shibahara, J., Taniguchi, H., Ishikawa, S., Ito, H., Yamamoto, S., Iwanari, H., Hironaka, M., Ishikawa, Y., Niki, T., Sohara, Y., Kodama, T., Nishimura, M., Fukayama, M., Dosaka-Akita, H., and Aburatani, H. (2005). Overexpression of the aldo-keto reductase family protein AKR1B10 is highly correlated with smokers'nonsmall cell lung carcinomas. Clin. Cancer Res. 11, 1776-1785.
23. Gagnon, I., Duester, G., and Bhat, P. V. (2002). Kinetic analysis of mouse retinal dehydrogenase type-2 (RALDH2) for retinal substrates. Biochim. Biophys. Acta 1596, 156-162.
24. Gallego, O., Belyaeva, O. V., Porté, S., Ruiz, F. X., Stetsenko, A. V., Shabrova, E. V., Kostereva, N. V., Farrés, J., Parés, X., and Kedishvili, N. Y. (2006). Comparative functional analysis of human medium-chain dehydrogenases, short-chain dehydrogenases/reductases and aldoketo reductases with retinoids. Biochem. J. 399, 101-109.
25. Gallego, O., Belyaeva, O. V., Porté, S., Ruiz,F. X.,Stetsenko,A.V.,Shabrova, E. V., Kostereva, N. V., Martras, S., Parés, X., Kedishvili, N. Y., and Farrés, J. (2007a). " Kinetic analysis of SDRs, ADHs and AKRs toward free and CRBPI-bound retinoids: effect of tween-80 and microsomal membranes," in Enzymology and Molecular Biology of Carbonyl Metabolism 13, eds H. Weiner, R. Lindahl, E. Maser, and B. Plapp (West Lafayette, IN: Purdue University Press), 144-151.
26. Gallego, O., Ruiz, F. X., Ardèvol, A., Domínguez, M., Álvarez, R., De Lera, A. R., Rovira, C., Farrés, J., Fita, I., and Parés, X. (2007b). Structural basis for the high alltrans-retinaldehyde reductase activity of the tumor marker AKR1B10. Proc. Natl. Acad. Sci. U.S.A. 104, 20764-20769.
27. Ghyselinck, N. B., Bavik, C., Sapin, V., Mark, M., Bonnier, D., Hindelang, C., Dierich, A., Nilsson, C. B., Hakansson, H., Sauvant, P., Azais-Braesco, V., Frasson, M., Picaud, S., and Chambon, P. (1999). Cellular retinol-binding protein I is essential for vitamin A homeostasis. EMBO J. 18, 4903-4914.
28. Gough,W. H.,Vanooteghem, S., Sint, T., and Kedishvili, N. Y. (1998). cDNA cloning and characterization of a new human microsomal NAD+dependent dehydrogenase that oxidizes all-trans-retinol and 3alpha-hydroxysteroids. J. Biol. Chem. 273, 19778-19785.
29. Graham, C. E., Brocklehurst, K., Pickersgill, R. W., and Warren, M. J. (2006). Characterization of retinaldehyde dehydrogenase 3. Biochem. J. 394, 67-75.
30. Grimshaw, C. E., and Mathur, E. J. (1989). Immunoquantitation of aldose reductase in human tissues. Anal. Biochem. 176, 66-71.
31. Harrison, E. H. (2012). Mechanisms involved in the intestinal absorption of dietary vitamin A and provitamin A carotenoids. Biochim. Biophys. Acta 1821, 70-77.
32. Herr, F. M., Li, E., Weinberg, R. B., Cook, V. R., and Storch, J. (1999). Differential mechanisms of retinoid transfer from cellular retinol binding proteins types I and II to phospholipid membranes. J. Biol. Chem. 274, 9556-9563.
33. Hollander, D., and Muralidhara, K. S. (1977). Vitamin A1 intestinal absorption in vivo: influence of luminal factors on transport. Am. J. Physiol. 232, E471-E477.
34. Howard, E. I., Sanishvili, R., Cachau, R. E., Mitschler, A., Chevrier, B., Barth, P., Lamour, V., Van Zandt, M., Sibley, E., Bon, C., Moras, D., Schneider, T. R., Joachimiak, A., and Podjarny, A. (2004). Ultrahigh resolution drug design I: details of interactions in human aldose reductaseinhibitor complex at 0.66 A. Proteins 55, 792-804.
35. Hyndman, D. J., and Flynn, T. G. (1998). Sequence and expression levels in human tissues of a new member of the aldo-keto reductase family. Biochim. Biophys. Acta 1399, 198-202.
36. Jez, J. M., Flynn, T. G., and Penning, T. M. (1997). A new nomenclature for the aldo-keto reductase superfamily. Biochem. Pharmacol. 54, 639-647.
37. Jin, Y., and Penning, T. M. (2006). Multiple steps determine the overall rate of the reduction of 5alpha-dihydrotestosterone catalyzed by human type 3 3alphahydroxysteroid dehydrogenase: implications for the elimination of androgens. Biochemistry 45, 13054-13063.
38. Jin, Y., and Penning, T. M. (2007). Aldo-keto reductases and bioactivation/detoxication. Annu.Rev.Pharmacol. Toxicol. 47, 263-292.
39. Joshi, A., Rajput, S., Wang, C., Ma, J., and Cao, D. (2010). Murine aldoketo reductase family 1 subfamily B: identification of AKR1B8 as an ortholog of human AKR1B10. Biol. Chem. 391, 1371-1378.
40. Kane, M. A. (2012). Analysis, occurrence, and function of 9-cis-retinoic acid. Biochim. Biophys. Acta 1821, 10-20.
41. Kane, M. A., Bright, F. V., and Napoli, J. L. (2011). Binding affinities of CRBPI and CRBPII for 9-cisretinoids. Biochim. Biophys. Acta 1810, 514-518.
42. Kane, M. A., Folias, A. E., Pingitore, A., Perri, M., Obrochta, K. M., Krois, C. R., Cione, E., Ryu, J. Y., and Napoli, J. L. (2010). Identification of 9-cis-retinoic acid as a pancreasspecific autacoid that attenuates glucose-stimulated insulin secretion. Proc. Natl. Acad. Sci. U.S.A. 107, 21884-21889.
43. Kedishvili, N. Y., Chumakova, O. V., Chetyrkin, S. V., Belyaeva, O. V., Lapshina, E. A., Lin, D. W., Matsumura, M., and Nelson, P. S. (2002). Evidence that the human gene for prostate short-chain dehydrogenase/reductase (PSDR1) encodes a novel retinal reductase (RalR1). J. Biol. Chem. 277, 28909-28915.
44. King, G., and Holmes, R. (1998). Human ocular aldehyde dehydrogenase isozymes: distribution and properties as major soluble proteins in cornea and lens. J. Exp. Zool. 282, 12-17.
45. Kumar, S., Sandell, L. L., Trainor, P. A., Koentgen, F., and Duester, G. (2012). Alcohol and aldehyde dehydrogenases: retinoid metabolic effects in mouse knockout models. Biochim. Biophys. Acta 1821, 198-205.
46. Lin, M., and Napoli, J. L. (2000). cDNA cloning and expression of a human aldehyde dehydrogenase (ALDH) active with 9-cis-retinal and identification of a rat ortholog, ALDH12. J. Biol. Chem. 275, 40106-40112.
47. Lobo, G. P.,Amengual, J., Palczewski, G., Babino, D., and Von Lintig, J. (2012). Mammalian carotenoid-oxygenases: key players for carotenoid function and homeostasis. Biochim. Biophys. Acta 1821, 78-87.
48. Lovering, A. L., Ride, J. P., Bunce, C. M., Desmond, J. C., Cummings, S. M., and White, S. A. (2004). Crystal structures of prostaglandin D(2) 11-ketoreductase (AKR1C3) in complex with the nonsteroidal antiinflammatory drugs flufenamic acid and indomethacin. Cancer Res. 64, 1802-1810.
49. MacLeod, A. K., Mcmahon, M., Plummer, S. M., Higgins, L. G., Penning, T. M., Igarashi, K., and Hayes, J. D. (2009). Characterization of the cancer chemopreventive NRF2dependent gene battery in human keratinocytes: demonstration that the KEAP1-NRF2 pathway, and not the BACH1-NRF2 pathway, controls cytoprotection against electrophiles as well as redox-cycling compounds. Carcinogenesis 30, 1571-1580.
50. Martin, H. J., and Maser, E. (2009). Role of human aldo-keto-reductase AKR1B10 in the protection against toxic aldehydes. Chem. Biol. Interact. 178, 145-150.
51. Martras, S., Álvarez, R., Gallego, O., Domínguez, M., De Lera, A. R., Farrés, J., and Parés, X. (2004). Kinetics of human alcohol dehydrogenase with ring-oxidized retinoids: effect of Tween 80. Arch. Biochem. Biophys. 430, 210-217.
52. Mertz, J. R., Shang, E., Piantedosi, R., Wei, S., Wolgemuth, D. J., and Blaner, W. S. (1997). Identification and characterization of a stereospecific human enzyme that catalyzes 9-cis-retinol oxidation. A possible role in 9-cis-retinoic acid formation. J. Biol. Chem. 272, 11744-11749.
53. Napoli, J. L. (1999). Interactions of retinoid binding proteins and enzymes in retinoid metabolism. Biochim. Biophys. Acta 1440, 139-162.
54. Novotna, R., Wsol, V., Xiong, G., and Maser, E. (2008). Inactivation of the anticancer drugs doxorubicin and oracin by aldo-keto reductase (AKR) 1C3. Toxicol. Lett. 181, 1-6.
55. Parés, X., Farrés, J., Kedishvili, N., and Duester, G. (2008). Mediumand short-chain dehydrogenase/reductase gene and protein families: medium-chain and shortchain dehydrogenases/reductases in retinoid metabolism. Cell.Mol.Life Sci. 65, 3936-3949.
56. Penning, T. M. (2005). AKR1B10: a new diagnostic marker of non-small cell lung carcinoma in smokers. Clin. Cancer Res. 11, 1687-1690.
57. Penning, T. M., Burczynski, M. E., Jez, J. M., Hung, C. F., Lin, H. K., Ma, H., Moore, M., Palackal, N., and Ratnam, K. (2000). Human 3alpha-hydroxysteroid dehydrogenase isoforms (AKR1C1-AKR1C4) of the aldo-keto reductase superfamily: functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormones. Biochem. J. 351, 67-77.
58. Penning, T. M., and Byrns, M. C. (2009). Steroid hormone transforming aldoketo reductases and cancer. Ann. N. Y. Acad. Sci. 1155, 33-42.
59. Penning, T. M., and Drury, J. E. (2007). Human aldo-keto reductases: function, gene regulation, and single nucleotide polymorphisms. Arch. Biochem. Biophys. 464, 241-250.
60. Penning, T. M., Jin, Y., Steckelbroeck, S., Lanisnik Rizner, T., and Lewis, M. (2004). Structure-function of human 3 alpha-hydroxysteroid dehydrogenases: genes and proteins. Mol. Cell. Endocrinol. 215, 63-72.
61. Penning, T. M., and Lerman, C. (2008). Genomics of smoking exposure and cessation: lessons for cancer prevention and treatment. Cancer Prev. Res. (Phila.) 1, 80-83.
62. Pogenberg, V., Guichou, J. F., Vivat-Hannah, V., Kammerer, S., Perez, E., Germain, P., De Lera, A. R., Gronemeyer, H., Royer, C. A., and Bourguet, W. (2005). Characterization of the interaction between retinoic acid receptor/retinoid X receptor (RAR/RXR) heterodimers and transcriptional coactivators through structural and fluorescence anisotropy studies. J. Biol. Chem. 280, 1625-1633.
63. Quick, T. C., and Ong, D. E. (1990). Vitamin A metabolism in the human intestinal Caco-2 cell line. Biochemistry 29, 11116-11123.
64. Quinn, A. M., Harvey, R. G., and Penning, T. M. (2008). Oxidation of PAH trans-dihydrodiols by human aldo-keto reductase AKR1B10. Chem. Res. Toxicol. 21, 2207-2215.
65. Ruiz, F. X., Gallego, O., Ardèvol, A., Moro, A., Domínguez, M., Álvarez, S., Álvarez, R., De Lera, A. R., Rovira, C., Fita, I., Parés, X., and Farrés, J. (2009). Aldoketo reductases from the AKR1B subfamily: retinoid specificity and control of cellular retinoic acid levels. Chem. Biol. Interact. 178, 171-177.
66. Ruiz, F. X., Moro, A., Gallego, O., Ardèvol, A., Rovira, C., Petrash, J. M., Parés, X., and Farrés, J. (2011a). Human and rodent aldo-keto reductases from the AKR1B subfamily and their specificity with retinaldehyde. Chem. Biol. Interact. 191, 199-205.
67. Ruiz, F. X., Porté, S., Gallego, O., Moro, A., Ardèvol, A., Del Río, A., Rovira, C., Farrés, J., and Parés, X. (2011b). Retinaldehyde is a substrate for human aldo-keto reductases of the 1C subfamily. Biochem. J. 440, 335-344.
68. Shen, Y., Zhong, L., Johnson, S., and Cao, D. (2011). Human aldo-keto reductases 1B1 and 1B10: a comparative study on their enzyme activity toward electrophilic carbonyl compounds. Chem. Biol. Interact. 191, 192-198.
69. Shirakami, Y., Lee, S. A., Clugston, R. D., and Blaner, W. S. (2012). Hepatic metabolism of retinoids and disease associations. Biochim. Biophys. Acta 1821, 124-136.
70. Tammali, R., Ramana, K. V., Singhal, S. S., Awasthi, S., and Srivastava, S. K. (2006). Aldose reductase regulates growth factor-induced cyclooxygenase-2 expression and prostaglandin E2 production in human colon cancer cells. Cancer Res. 66, 9705-9713.
71. Tang, X. H., and Gudas, L. J. (2011). Retinoids, retinoic acid receptors, and cancer. Annu. Rev. Pathol. 6, 345-364.
72. Theodosiou, M., Laudet, V., and Schubert, M. (2010). From carrot to clinic: an overview of the retinoic acid signaling pathway. Cell. Mol. Life Sci. 67, 1423-1445.
73. Verma, M., Martin, H. J., Haq, W., O'Connor, T. R., Maser, E., and Balendiran, G. K. (2008). Inhibiting wild-type and C299S mutant AKR1B10; a homologue of aldose reductase upregulated in cancers. Eur. J. Pharmacol. 584, 213-221.
74. Wang, C., Yan, R., Luo, D., Watabe, K., Liao, D. F., and Cao, D. (2009). Aldo-keto reductase family 1 member B10 promotes cell survival by regulating lipid synthesis and eliminating carbonyls. J. Biol. Chem. 284, 26742-26748.
75. Wang, R., Wang, G., Ricard, M. J., Ferris, B., Strulovici-Barel, Y., Salit, J., Hackett, N. R., Gudas, L. J., and Crystal, R. G. (2010). Smokinginduced upregulation of AKR1B10 expression in the airway epithelium of healthy individuals. Chest 138, 1402-1410.
76. Xi, J., and Yang, Z. (2008). Expression of RALDHs (ALDH1As) and CYP26s in human tissues and during the neural differentiation of P19 embryonal carcinoma stem cell. Gene Expr. Patterns 8, 438-442.
77. Yoshida, A., Hsu, L. C., and Dave, V. (1992). Retinal oxidation activity and biological role of human cytosolic aldehyde dehydrogenase. Enzyme 46, 239-244.
78. Zeindl-Eberhart, E., Haraida, S., Liebmann, S., Jungblut, P. R., Lamer, S., Mayer, D., Jager, G., Chung, S., and Rabes, H. M. (2004). Detection and identification of tumor-associated protein variants in human hepatocellular carcinomas. Hepatology 39, 540-549.
79. Zhong, L., Shen, H., Huang, C., Jing, H., and Cao, D. (2011). AKR1B10 induces cell resistance to daunorubicin and idarubicin by reducing C13 ketonic group. Toxicol. Appl. Pharmacol. 255, 40-47.